6 completed, 1 withdrawn. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 6, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
Follow Bacterial Infection: new trials by email Literature Review of Bacterial Infection trials Research Report on Bacterial Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam AZACTAM, Ceftazidime-Avibactam - Bacterial Infection | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | 2019-07-09 | 2022-06-07 |
| Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites MBN-101, Placebo - Bacterial Infection | Phase 2 | Completed | Microbion Corporation | 29 | 2016-05-24 | 2021-09-30 |
| Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections Daptomycin, Brilacidin - Skin Infection, Bacterial Infection | Phase 2 | Completed | Cellceutix Corporation | 215 | 2014-02-01 | 2018-09-26 |
| Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings Group B Streptococcus Trivalent Vaccine, Placebo - Streptococcal Infection, Gram-positive Bacterial Infection | Phase 2 | Completed | Novartis | 86 | 2011-09-01 | 2014-09-08 |
| Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients human lactoferrin (hLF1-11) - Fungal Infection, Bacterial Infection | Phase 1 / Phase 2 | Withdrawn | AM-Pharma | 2008-11-01 | 2015-06-30 | |
| Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections ceftaroline, linezolid, Aztreonam - Bacterial Infection | Phase 2 | Completed | Forest Laboratories | 150 | 2008-02-01 | 2017-03-14 |
| Effect of Chlorhexidine Cleansing on Skin Flora of Newborns in Nepal skin cleansing with chlorhexidine (0.25%, 0.5%, 1%) - Bacterial Infection | Phase 1 / Phase 2 | Completed | Johns Hopkins Bloomberg School of Public Health | 286 | 2006-01-01 | 2010-04-05 |
Bacterial Infections (7) · Abscess (2) · Cellulitis (2) · Gram-Positive Bacterial Infections (2) · Infections (2) · Wound Infection (2) · Erysipelas (1) · Fractures, Bone (1) · Gram-Negative Bacterial Infections (1) · Inflammation (1) · Mycoses (1) · Neutropenia (1) · Osteomyelitis (1) · Staphylococcal Infections (1) · Streptococcal Infections (1)
Bacterial Infections and Mycoses (7) · Infections (5) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Connective Tissue Diseases (2) · Inflammation (2) · Skin Diseases, Infectious (2) · Skin and Connective Tissue Diseases (2) · Suppuration (2) · Agranulocytosis (1) · Bone Diseases (1) · Bone Diseases, Infectious (1) · Cytopenia (1) · Gram-Positive Bacterial Infections (1) · Hematologic Diseases (1)
Aztreonam (2) · Ceftaroline (1) · Chlorhexidine (1) · Daptomycin (1) · Injections (1) · Linezolid (1) · avibactam, ceftazidime drug combination (1) · brilacidin (1)
AM-Pharma (1) · Cellceutix Corporation (1) · Forest Laboratories (1) · Johns Hopkins Bloomberg School of Public Health (1) · Microbion Corporation (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis (1)
United States (4) · Belgium (1) · Canada (1) · Nepal (1) · Netherlands (1)
Brett Baker, MSc, DC (1) · Gilbert Donders, Prof. (1) · Luke C Mullany, PhD (1) · Peter J Donnelly, PhD (1) · William O'Riordan, MD (1)
5UM1AI104681-09 (1), R01HD044004 (1)